Investment
Features
FeesSafety
Academy
More
Pluang+

MySize plans to grow via selective acquisitions in defense technology, diversifying beyond fashion tech.

Company Fundamentals
14 Sep 2026
PRNewsWire
View Source
Bullish
MySize plans to grow via selective acquisitions in defense technology, diversifying beyond fashion tech.

MySize, Inc. announced a new growth strategy focused on acquiring defense technology companies to build a platform over time. The company will evaluate potential targets based on technology, commercial strength, and financial health, aiming for sustainable long-term growth. This marks a strategic shift from its current fashion technology business. MySize has not set a timeline or number of acquisitions and may seek additional financing, which could dilute existing shareholders.

MySize's new acquisition-led strategy in defense technology is presented here with a snapshot of the Technology sector on Pluang. For readers following Technology stocks, as of Sep 14, 2026 19:01 WIB, out of 150 priced US stocks, 71 rose and 74 fell. Notable price changes include Teradyne, Inc. (TER) down 7.20% at USD 352.52, Marathon Digital Holdings Inc (MARA) down 7.01% at USD 11.14, and Entegris Inc (ENTG) down 6.68% at USD 131.00.

More News

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
3 hours ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
3 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
4 hours ago
Shiba Inu euro trading shows wide spread gaps, impacting trader costs across exchanges.

Shiba Inu euro trading shows wide spread gaps, impacting trader costs across exchanges.

On October 19, Shiba Inu (SHIB) trading against the euro revealed significant differences in bid-ask spreads across exchanges, with Kraken and Bit2Me showing tight spreads around 0.022%, while WhiteBIT had a much wider spread of 0.670%. This large va...

Market News
Neutral
4 hours ago
Socialism gains political ground in US, prompting free market advocates to strengthen their case for capitalism.

Socialism gains political ground in US, prompting free market advocates to strengthen their case for capitalism.

Socialism is rising in popularity within U.S. politics, particularly among those identifying as democratic socialists who seek a system more like European social democracy. Sam Gregg of the American Institute for Economic Research highlights the need...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App